Skip to main content
Fig. 8 | Cancer Cell International

Fig. 8

From: Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma

Fig. 8

Potential therapeutic drugs for Group 4 based on T cell expression. a Group 4 had a higher level of T cell dysfunction than the other subgroups. bs Eighteen drugs with obvious differences in sensitivity in Group 4. These results indicate that Group 4 is more sensitive to EHT 1864, FH535, and lapatinib chemotherapy than the other groups

Back to article page